Virus-Boosted immune cells take on tough melanoma
NCT ID NCT06961786
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new approach for advanced melanoma that has not responded to standard treatments. Nine patients will receive a modified virus (TILT-123) designed to deliver immune-boosting signals directly into tumors, along with their own tumor-fighting immune cells (TILs) and chemotherapy. The main goal is to check safety and tolerability, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TILT-123 (a modified virus that delivers TNFa and IL-2) combined with tumor-infiltrating lymphocytes (TILs) and chemotherapy (cyclophosphamide and fludarabine)
- What this could lead to
- If this approach is safe and shows promise, it could point toward a new combination therapy for advanced melanoma that has stopped responding to other treatments.
- What could go wrong
- This is a very early phase 1 trial with only 9 people, focused on safety not effectiveness. The virus and cell therapy may cause serious side effects, and the treatment may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University
Copenhagen, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma